Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DKK1
REST API REST API
Homo sapiens
DKK1 is differentially expressed in 257 experiments: 101 organism parts: placenta, lung, ... (99 more);, 174 disease states: normal, prostate carcinoma, ... (172 more);, 95 cell types 459 cell lines 41 compound treatments and 69 other conditions.
Synonyms DKK-1, SK
Orthologs Q8UUX3_CHICK (Gallus gallus)   Q4H3Q2_CIOIN (Ciona intestinalis)   dkk1b (Danio rerio)   Dkk1 (Mus musculus)   DKK1 (Bos taurus)   Dkk1 (Rattus norvegicus)   dkk1 (Xenopus laevis)   DKK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, mesoderm formation, receptor antagonist activity, cell morphogenesis involved in differentiation, protein binding, extracellular space, endoderm formation, growth factor activity, extracellular region, negative regulation of Wnt receptor signaling pathway, signal transducer activity, endoderm development, multicellular organismal development, negative regulation of BMP signaling pathway, regulation of Wnt receptor signaling pathway, negative regulation of transcription from RNA polymerase II promoter, signal transduction, head morphogenesis, hair follicle development, forebrain development, response to retinoic acid, negative regulation of peptidyl-serine phosphorylation, embryonic limb morphogenesis, negative regulation of canonical Wnt receptor signaling pathway, negative regulation of skeletal muscle tissue development, face morphogenesis, negative regulation of protein complex assembly, Wnt receptor signaling pathway involved in somitogenesis, regulation of receptor internalization, low-density lipoprotein particle receptor binding, positive regulation of heart induction by negative regulation of canonical Wnt receptor signaling pathway
InterPro Term Dickkopf_N
UniProt Accession O94907
Search EB-eye ENSG00000107984
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
PC3
3
E-GEOD-5258, E-GEOD-14464, E-MEXP-2034
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
HL-60
2
E-GEOD-5258, E-MTAB-37
LNCaP
2
E-GEOD-14464, E-GEOD-14990
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
453 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-19397, ... (41 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
fibroblast
2
E-GEOD-3204, E-MEXP-466
embryonic stem cell
1
2
E-MEXP-930, E-GEOD-2248, E-MEXP-2426
neuroepithelial cell
1
E-MEXP-2426
epidermoid
1
E-GEOD-19397
hMOF over-expressed
1
E-GEOD-20193
89 more value(s).


Disease state

studied in E-GEOD-3860, E-MEXP-1922, E-GEOD-15960, E-MEXP-1121, E-TABM-26, ... (42 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
prostate carcinoma
2
4
E-MEXP-2034, E-MTAB-37, E-GEOD-96, E-MTAB-62, E-MEXP-1327, ... (6 experiments)
glioblastoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-4290, E-MEXP-567
AIDS-KS, KSHV-
2
E-MEXP-66, E-MTAB-62
healthy
2
E-GEOD-14895, E-GEOD-19188
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
168 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-1417, E-GEOD-697, E-GEOD-5824, ... (21 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
phenol
1
E-GEOD-6907
dimethyl sulfoxide
1
E-GEOD-5824
Cxcl12
1
E-GEOD-7307
unknown
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-755, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, E-MEXP-1235, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-6432, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-1926, E-GEOD-19330, E-GEOD-19519, E-GEOD-6919, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-GEOD-2077, E-MEXP-561

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-4600 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-1703, E-GEOD-12438, E-GEOD-1676, ... (9 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19815, E-GEOD-15799

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.551 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM